BR112013028197A2 - compostos de benzofurano-piperidina - Google Patents

compostos de benzofurano-piperidina

Info

Publication number
BR112013028197A2
BR112013028197A2 BR112013028197A BR112013028197A BR112013028197A2 BR 112013028197 A2 BR112013028197 A2 BR 112013028197A2 BR 112013028197 A BR112013028197 A BR 112013028197A BR 112013028197 A BR112013028197 A BR 112013028197A BR 112013028197 A2 BR112013028197 A2 BR 112013028197A2
Authority
BR
Brazil
Prior art keywords
benzofuran
piperidine compounds
formula
compounds
relates
Prior art date
Application number
BR112013028197A
Other languages
English (en)
Inventor
Juergen Wichmann
Rosa Maria Rodriguez Sarmiento
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013028197A2 publication Critical patent/BR112013028197A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo patente de invenção: "compostos de benzofurano-piperidina". a presente invenção refere-se a novos moduladores duplos seletivos dos receptores 5-ht2a e d3 de fórmula (i) (i) em que r1, r2, r3, n, e y são como descrito neste relatório, assim como a sais e ésteres farmaceuticamente aceitáveis dos mesmos. além disso, a presente invenção refere-se à produção dos compostos de fórmula (i), a composições farmacêuticas compreendendo os mesmos e ao uso dos mesmos como medicamentos.
BR112013028197A 2011-05-04 2012-05-02 compostos de benzofurano-piperidina BR112013028197A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11164716 2011-05-04
PCT/EP2012/057965 WO2012150231A1 (en) 2011-05-04 2012-05-02 Novel benzofurane-piperidine compounds

Publications (1)

Publication Number Publication Date
BR112013028197A2 true BR112013028197A2 (pt) 2017-01-17

Family

ID=46044685

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028197A BR112013028197A2 (pt) 2011-05-04 2012-05-02 compostos de benzofurano-piperidina

Country Status (10)

Country Link
US (1) US8921397B2 (pt)
EP (1) EP2704707A1 (pt)
JP (1) JP2014513109A (pt)
KR (1) KR20140037106A (pt)
CN (1) CN103501780B (pt)
BR (1) BR112013028197A2 (pt)
CA (1) CA2832302A1 (pt)
MX (1) MX2013011728A (pt)
RU (1) RU2013152142A (pt)
WO (1) WO2012150231A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
CN111801330B (zh) 2018-01-26 2024-04-05 盐野义制药株式会社 具有多巴胺d3受体拮抗作用的稠环化合物
WO2019146740A1 (ja) * 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
DK60693D0 (da) 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
DE69812980T2 (de) 1997-02-07 2003-11-13 Aventis Pharma Inc (4-piperidinyl)-1h-2-benzopyran derivate verwendbar als antipsychotische mittel
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
ES2131020B1 (es) 1997-10-13 2000-03-01 Lacer Sa Derivados de benzofurano, dihidrobenzofunaro, dihidrobenzopirano y benzopirano como agentes antidepresivos.
WO1999040067A2 (en) 1998-02-09 1999-08-12 Duphar International Research B.V. Benzisoxazole derivatives having d4-antagonistic activity
GB0117577D0 (en) * 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
JP4497815B2 (ja) 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な複素環式アミド誘導体およびドーパミンｄ３受容体リガンドとしてのその使用
ATE412638T1 (de) 2001-02-16 2008-11-15 Aventis Pharma Inc Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden
GB0117950D0 (en) 2001-02-16 2001-09-19 Aventis Pharma Inc Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands
JP2006503106A (ja) 2002-09-17 2006-01-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 統合失調症を処置するためのヘテロ環式置換ピペラジン
CA2525866A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
BRPI0410419A (pt) 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
HUP0500170A3 (en) 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
BRPI0707960A2 (pt) 2006-02-17 2011-05-10 Hoffmann La Roche derivados de benzoil-piperidina como moduladores de 5ht2/d3, medicamento e uso dos mesmos
EP1870405A1 (en) 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
AU2007316249B2 (en) 2006-10-31 2013-01-24 F. Hoffmann-La Roche Ag Ether derivatives dual modulators of the 5-HT2A and D3 receptors
AU2008280187B2 (en) 2007-07-26 2013-05-16 F. Hoffmann-La Roche Ag Dual modulators of 5-HT2A and D3 receptors
CA2694057A1 (en) 2007-08-09 2009-02-12 F. Hoffmann-La Roche Ag Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors
AU2009294695B2 (en) 2008-09-22 2012-09-13 F. Hoffmann-La Roche Ag Piperazine D3 and 5-HT2a receptor modulators
JP2012502948A (ja) 2008-09-23 2012-02-02 エフ．ホフマン−ラ ロシュ アーゲー ドーパミンｄ３受容体の調節剤として有用なイソオキサゾロ［４，５］ピリジン−３−イル−ピペラジン誘導体
JP2012502947A (ja) 2008-09-23 2012-02-02 エフ．ホフマン−ラ ロシュ アーゲー ドーパミンＤ３受容体の調節剤として有用なベンゾ［ｄ］イソオキサゾール−３−イル−ピペラジン誘導体
WO2010034648A1 (en) 2008-09-23 2010-04-01 F. Hoffmann-La Roche Ag Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors
US8586579B2 (en) 2010-06-21 2013-11-19 Hoffmann-La Roche Inc. Anellated pyridine compounds
US8470828B2 (en) 2010-07-06 2013-06-25 Hoffmann-La Roche Inc. Anellated pyridine compounds

Also Published As

Publication number Publication date
CN103501780A (zh) 2014-01-08
MX2013011728A (es) 2013-11-01
CN103501780B (zh) 2015-11-25
WO2012150231A1 (en) 2012-11-08
US8921397B2 (en) 2014-12-30
EP2704707A1 (en) 2014-03-12
US20120283254A1 (en) 2012-11-08
RU2013152142A (ru) 2015-06-10
CA2832302A1 (en) 2012-11-08
KR20140037106A (ko) 2014-03-26
JP2014513109A (ja) 2014-05-29

Similar Documents

Publication Publication Date Title
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
NI201400108A (es) Compuestos de heterociclilo
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
BR112015006436A2 (pt) novas piridinonas bicíclicas
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
UY33044A (es) Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
BR112013000189A2 (pt) compostos de piridina anelados
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
BR112012032748A2 (pt) "compostos de piridina anelados"
BR112014027359A2 (pt) moduladores da série de reação complementar e usos dos mesmos
BR112013000059A2 (pt) derivados de piperidina e seus usos para o tratamento de distúrbios metabólicos
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112012012261A2 (pt) compostos como moduladores de receptor com utilidade terapêutica
EA201792597A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
EA201400854A1 (ru) 4-(бензоимидазол-2-ил)тиазольные соединения и родственные аза производные
TR201902057T4 (tr) Tetrasiklin bileşikleri.
BR112013019844A2 (pt) compostos de benzodioxol piperidina
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
ECSP13012838A (es) Nuevos compuestos de benzodioxol-piperazina
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
MX2013005966A (es) Nuevos compuestos de benzofurano.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]